Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT$_{1A}$ agonists

Ana P. Abdala$^1$, John M. Bissonnette$^2$ and Adrian Newman-Tancredi$^3$

$^1$ School of Physiology and Pharmacology, University of Bristol, Bristol, UK
$^2$ Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA
$^3$ Neurolix Inc., Dana Point, CA, USA

Rett syndrome is a neurological disorder caused by loss of function of methyl-CpG-binding protein 2 (MeCP2). This syndrome is most often linked to mutations in the X-linked gene that encodes this protein. The loss of function of this ubiquitous transcriptional regulator has a devastating effect in particular on the central nervous system. The syndrome presents with cortical features, including severe mental disability and epilepsy (Dolce et al., 2013); and extrapyramidal symptoms, resulting in dystonia and dyskinesia (Chahroud and Zoghbi, 2007). However, a life-threatening presentation of this syndrome is brainstem dysfunction, which results in breathing disturbances. This phenotype, mimicked by the mouse models of Rett, is deemed the most reliable outcome measure for clinical translation (Katz et al., 2012). Like most phenotypes in Rett, the presentation of respiratory disturbances is highly variable, but typically includes episodes of breathing cessation interspersed with hyperventilation or irregular breathing (Ramirez et al., 2013). Defects in various neurotransmitter systems have been observed in patients and animal models of Rett syndrome (Weng et al., 2011), but we believe serotonin (5-HT) deserves particular interest due to its role in promoting regular breathing, increasing vagal tone, regulating mood, alleviating Parkinsonian-like symptoms and potential for therapeutic translation. A promising new symptomatic strategy currently focuses on regulation of serotonergic function using highly selective serotonin type 1A (5-HT$_{1A}$) “biased agonists.” We address this newly emerging therapy for respiratory brainstem dysfunction and challenges for translation with a holistic perspective of Rett syndrome, considering potential mood and motor effects.

SEROTONIN AND AUTONOMIC CONTROL IN RETT SYNDROME

Deficiencies of 5-HT neurotransmission have been found both in humans suffering from Rett syndrome and in mouse models of the disease. In women with known MeCP2 mutations who met the clinical criteria for Rett syndrome, low spinal fluid levels of a 5-HT metabolite were found (Samaco et al., 2009). Low levels of 5-HT were also found in the brain of MeCP2 knockout male mice and were progressive with development (Ide et al., 2005; Viemari et al., 2005). But brain concentrations of tryptophan, the serotonin precursor, were comparable to wild-type control mice suggesting a failure of biosynthesis of serotonin (Ide et al., 2005).

Serotonin is an important regulatory neurotransmitter in the respiratory network. Generally it has a modulatory effect on breathing, increasing or decreasing post-synaptic excitability depending on the types of receptors expressed. Overall, the effect of 5-HT results in net stimulation of ventilation, and it is a significant component of ventilatory responses to CO$_2$ (Richerson, 2004). Global deletion or acute inhibition of serotoninergic neurons in mice results in blunted respiratory responses to CO$_2$ challenges (Hodges et al., 2008; Ray et al., 2011). Deletion of MeCP2 in male mice reduced CO$_2$ sensitivity (Zhang et al., 2011) and selective blockade of serotonin re-uptake with citalopram corrected it (Toward et al., 2013). Recently, female mice with two different MeCP2 mutations have shown depressed CO$_2$ chemosensitivity (Bissonnette et al., 2014). Imbalance in CO$_2$ homeostasis was also found in human patients (Smeets et al., 2006). Forceful breathing and
Serotonin is also important for cardiac sympa-thovagal balance. Serotonergic agonists shift the equilibrium between cardiac sympathetic and vagal drives toward the latter, which has a protective effect against ventricular fibrillation (Lehnert et al., 1987; McCall et al., 1994; Chen et al., 2008). Chen et al. (2008) showed that a 5-HT_{1A/7} agonist disinhibited vagal motor neurons via reduction of inputs from inhibitory neurons. In mice, deletion of 5-HT_{1A} receptors increased the susceptibility to sudden cardiac death under chronic stress (Carnevali et al., 1999, 2004). Interestingly, girls with Rett syndrome present a lower heart rate variability, as consequence of a reduced vagal tonus, which correlated with lower plasma levels of serotonin (Guideri et al., 1999, 2004). The reduced vagal tonus is progressive with development and clinical stage, and may explain the high risk of sudden death in Rett syndrome (Kerr et al., 1997; Guideri et al., 2001). In a cohort of patients with normal cardiac vagal drive, the increase of vagal tonus induced by selective 5-HT_{1A} agonists would be an undesirable side effect, placing them at risk of atrial arrhythmias. In patients with Rett syndrome, who display a shifted set point of cardiac parasympathetic drive, the increase of vagal tonus induced by selective 5-HT_{1A} agonists would be a particularly desirable effect.
SLEEP DISORDERED BREATHING IN RETT SYNDROME

Another likely contributor for sympathetic overactivity in Rett syndrome is sleep disordered breathing. Recent polysomnography recordings in girls with Rett syndrome revealed that obstructive sleep apneas (OSAs) are highly prevalent in this population. During sleep, central apneas are less frequent and shorter when compared to wakefulness (Weese-Mayer et al., 2008). Even though central apneas are 10–30% more frequent than OSAs during sleep, the latter are clinically relevant in approximately 50% of the patients investigated, causing life threatening oxygen desaturations (SpO2 < 75%) (Hagebeuk et al., 2012; Carotenuto et al., 2013). In children, severe OSA has clear health implications, the common symptoms are: frequent awakenings, night terrors, poor concentration, irritability, behavioral problems, failure to thrive, enuresis, attention-deficit disorder, cardiopulmonary disease, and excessive daytime sleepiness (Waters et al., 2013). Most of these symptoms are easily confounded with the symptomatology of Rett syndrome itself. Unfortunately, this means that often, from a clinician’s point of view, OSA diagnosis and treatment is not a priority in Rett patients.

In fact, the high prevalence of OSAs is relevant for the treatment of respiratory disturbances in Rett syndrome since they have potential to generate a reciprocal feedback loop with central apneas resulting in respiratory irregularities. It is well established that OSAs increase peripheral chemoreceptor sensitivity in humans independently of other underlying conditions (Narkiewicz et al., 1999). In turn, excess activation of the peripheral chemoreceptor reflex during apnea-induced desaturations in Rett syndrome, could aggravate hyperventilation episodes in between apneas and generate hypocapnia. This type of respiratory overshoot is particularly undesirable during sleep, as PaCO2 reaches the apneic threshold resulting in periodic breathing (Dempsey et al., 2014). An overactive chemoreflex could also account for the sympatho-vagal imbalance common in patients with Rett (Guideri et al., 1999).

A pharmacotherapy capable of addressing all legs of this feedback loop would stand better chances of success in clinical practice. It is thought that, in the supine position, recruitment of the genioglossus can open a collapsed airway before arousal (Younes et al., 2012). For that reason, mechanisms that facilitate recruitment of hypoglossal motor neurons are an attractive target for pharmacotherapy. Rodent models revealed that the respiratory component of genioglossal activity is increased by 5-HT1A receptor activation, a potentially beneficial effect (Besnard et al., 2007). Another potentially advantageous effect of this class of drugs is the reduction of epochs of REM sleep (Monti and Monti, 2000), since OSAs mostly occur in this phase. The lack of success in previous clinical trials (Kohler et al., 2009) using various older serotonin agonists may be due to their lack of receptor selectivity, weak partial agonism and/or poor pharmacokinetics (Fiorino et al., in press).

SEROTONIN AND MOOD CONTROL IN RETT SYNDROME

Particularly in Rett syndrome, mood disorder should not be viewed as a separate entity to autonomic dysfunction, as anxiety features could have a role in episodes of hyperventilation. Southall et al. (1988) observed that hyperventilation only occurred in wakefulness and was not necessarily preceded by hypoxemia, which suggests a central origin. Prolonged absences of inspiratory effort always followed hyperventilation. These girls also seemed agitated with increased muscle tonus and elevated heart rate, suggesting that anxiety may underlie these symptoms. SSRIs such as citalopram or fluoxetine are commonly used to treat anxiety disorders in a clinical setting. By preventing reuptake of 5-HT, these drugs modify serotonin levels and, indirectly, activation of serotonin receptors. It should also be noted that 5-HT receptors are expressed in diverse brain regions and can mediate complementary or sometimes opposing influence on mood and cognition (Newman-Tancredi, 2011). For example, activation of 5-HT1A autoreceptors in the raphe nuclei can totally suppress electrical activity of serotonergic neurons and thus powerfully inhibit serotonin release in neuronal projection areas (Celada et al., 2013). In contrast, activation of post-synaptic cortical 5-HT1A hetero-receptors expressed on glutamatergic pyramidal cells and/or GABAergic interneurons, elicits increased dopamine release in cortex (Santana et al., 2004; Bortolozzi et al., 2010), an effect which is associated with beneficial effects on mood deficits as well as positive effects on cognitive function (Phillips et al., 2004).

In the case of RTT patients, lower basal levels of 5-HT are reported (see above) and some of the mood deficits observed in Rett syndrome patients may therefore arise from deficiencies in serotonergic transmission (particularly via 5-HT1A receptors) in specific brain regions. Such a hypothesis is reinforced by transgenic mouse studies that have provided insight into the developmental role of 5-HT1A receptors (Akimova et al., 2009; Garcia-Garcia et al., 2014). Thus, mice with a genetically-elicited deletion of 5-HT1A receptors (5-HT1A KO mice) exhibit heightened anxiety-like behavior, as do mice with a heterozygote 5-HT1A genotype that express about half of normal levels of 5-HT1A receptor density. This suggests that even partial decreases in 5-HT1A receptor expression (which may mimic the impaired serotonergic transmission observed in Rett syndrome) can elicit phenotypically-meaningful increases in anxiety levels. In contrast, when mice were engineered to overexpress 5-HT1A receptors (Kusserow et al., 2004), they exhibited the opposite phenotype, with decreased anxiety-like behavior and increased hippocampal and striatal levels of serotonin. An additional study investigated the reversal of the anxiety-like phenotype of 5-HT1A KO mice. In these mice, 5-HT1A receptors were overexpressed in pyramidal neurons (but not GABAergic interneurons; Gross et al., 2002), in various forebrain regions, and this re-established normal behavioral responses. This study is significant because it shows that the “anxious” phenotype of the KO mice can be rescued, if 5-HT1A receptor signaling is re-introduced to the relevant brain regions. Such observations support the assertion that treatments that augment 5-HT1A receptor signaling in appropriate forebrain structures can attenuate anxiety symptoms.

The possibility that mood deficits seen in Rett syndrome patients arise from neurodevelopmental disruption of 5-HT1A receptor expression is reinforced by studies showing that undisturbed expression of the 5-HT1A receptor is required in the 2nd
and 3rd week of life for the emergence of a normal anxiety-like phenotype. Indeed, genetic disruption of 5-HT\textsubscript{1A} receptors in mice at this time period elicits development of pathological levels of anxiety (Gross et al., 2002; Leonardo and Hen, 2008), an observation that can be mimicked by pharmacological blockade of 5-HT\textsubscript{1A} receptors (Lo Iacono and Gross, 2008).

Taken together, the above considerations suggest that activation of 5-HT\textsubscript{1A} receptors by administration of agonist drugs to Rett patients could attenuate anxiety symptoms in adults. In addition, if the heightened anxiety symptoms are the result of insufficient serotonergic activation during development, it may be speculated that treatment with a 5-HT\textsubscript{1A} agonist at a young age may exert some measure of protection against the emergence of later anxiety symptoms. Nevertheless, considerable additional investigation is necessary to substantiate such hypotheses, notably because none of the above studies on transgenic 5-HT\textsubscript{1A} mice was carried out in female MeCP2\textsuperscript{+/−} mice modeling Rett syndrome.

Indeed, studies of anxiety-like behavior in MeCP2\textsuperscript{+/−} mice have yielded somewhat divergent data. One study found that MeCP2\textsuperscript{+/−} female mice exhibited lower anxiety-like behavior in two different tests (Samaco et al., 2013). In contrast, another study in male mice expressing a truncated allele of MeCP2 (MeCP2\textsuperscript{108/3}) (McGill et al., 2006) found that MeCP2\textsuperscript{+/−} mice show responses that are typical of increased anxiety in the same tests. The relationship between these observations and the heightened anxiety observed in individuals with Rett syndrome is unclear, but there is a clear need for additional investigation of anxiety-like behavior in RTT mice, particularly in response to clinically-employed anxiolytic drugs and 5-HT\textsubscript{1A} receptor agonists.

### DOPAMINERGIC INTERACTIONS OF SEROTONINERGIC AGONISTS: IMPLICATIONS FOR MOTOR FUNCTION IN RETT SYNDROME

In women with known MeCP2 mutations who met the clinical criteria for Rett syndrome, low spinal fluid levels of a dopamine metabolite were found (Samaco et al., 2009). Assuming that this is a marker for central dopamine levels, it may provide a neurochemical substrate for the devastating disturbances in motor function observed in Rett syndrome, characterized by loss of purposive use of the hands, ataxia, tremors, gait apraxia, rigidity, and dystonia. Another indicator of compromised dopaminergic function could be found in the clinical trial data for a number of serotonin 5-HT\textsubscript{1A} receptor agonists.

---

#### Table 1 | Drugs currently under clinical testing that possess serotonin 5-HT\textsubscript{1A} receptor agonist activity.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical indication</th>
<th>Trade name\textsuperscript{®} or highest development</th>
<th>Company</th>
<th>Mechanism of action</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buspirone</td>
<td>Anxiety (GAD)</td>
<td>Buspar\textsuperscript{®}</td>
<td>BMS</td>
<td>5-HT\textsubscript{1A} partial agonist, D\textsubscript{2} antagonist</td>
<td>Akimova et al., 2009</td>
</tr>
<tr>
<td>Tandospirone</td>
<td>Anxiety (GAD)</td>
<td>Sediel\textsuperscript{®}</td>
<td>Dainippon Sumitomo</td>
<td>5-HT\textsubscript{1A} partial agonist, D\textsubscript{2} antagonist</td>
<td>Meitzer and Sumiyoshi, 2008</td>
</tr>
<tr>
<td>Vilazodone</td>
<td>Depression</td>
<td>Viibryd\textsuperscript{®}</td>
<td>Clinical Data</td>
<td>SRI, 5-HT\textsubscript{1A} partial agonist</td>
<td>Dawson and Watson, 2009</td>
</tr>
<tr>
<td>Vortioxetine</td>
<td>Depression</td>
<td>Brintellix\textsuperscript{®}</td>
<td>Lundbeck/Takeda</td>
<td>SRI; 5-HT\textsubscript{1A} and 5-HT\textsubscript{1B} partial agonist; 5-HT\textsubscript{1D}, 5-HT\textsubscript{3} and 5-HT\textsubscript{7} antagonist</td>
<td>Mork et al., 2009</td>
</tr>
<tr>
<td>Flibanserin</td>
<td>Female hypoactive sexual desire disorder</td>
<td>Phase III</td>
<td>Sprout</td>
<td>5-HT\textsubscript{1A} agonist, 5-HT\textsubscript{2A} antagonist, D\textsubscript{4} partial agonist</td>
<td>Stahl et al., 2011</td>
</tr>
<tr>
<td>Sarizotan</td>
<td>L-DOPA-induced dyskinesia in Parkinson's disease\textsuperscript{a}</td>
<td>Phase III</td>
<td>Newron</td>
<td>5-HT\textsubscript{1A} agonist, D\textsubscript{2} partial agonist</td>
<td>Bartoszyk et al., 2004</td>
</tr>
<tr>
<td>Befiradol</td>
<td>L-DOPA-induced dyskinesia in Parkinson's disease</td>
<td>Phase II</td>
<td>Neurolixis</td>
<td>Selective 5-HT\textsubscript{1A} full agonist</td>
<td>Colpaert, 2006</td>
</tr>
<tr>
<td>Eltoprazine</td>
<td>L-DOPA-induced dyskinesia in Parkinson's disease</td>
<td>Phase II</td>
<td>Amaranthus</td>
<td>5-HT\textsubscript{1A} and 5-HT\textsubscript{1B} partial agonist, 5-HT\textsubscript{2A}, 5-HT\textsubscript{2B}, 5-HT\textsubscript{3C}</td>
<td>Bezar et al., 2013</td>
</tr>
<tr>
<td>NLX-101 (F15599)</td>
<td>Rett syndrome</td>
<td>Phase I</td>
<td>Neurolixis</td>
<td>Selective post-synaptic 5-HT\textsubscript{1A} “biased agonist”</td>
<td>Levitt et al., 2013</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Sarizotan may also be developed for Rett syndrome (http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=141).

GAD, Generalized Anxiety Disorder; SRI, Serotonin Reuptake Inhibitor.
transmission is that, later in life, the women with Rett develop Parkinsonian features (Fitzgerald et al., 1990; Roze et al., 2007).

The precise role of serotonin in Rett syndrome motor deficits in currently unclear but some analogies may be drawn from the use of serotonergic agonists in the treatment of Parkinson's disease (PD)—which is also characterized by dopaminergic deficiencies leading to motor impairment. For example (i) 5-HT<sub>1A</sub> receptor agonists reverse catalepsy induced by blockade of dopamine receptors with neuroleptics (McMillen et al., 1988; Wadenberg, 1996); (ii) (+)-8-OH-DPAT and sarizotan reduced L-DOPA-induced dyskinesia in monkeys with lesioned dopaminergic neurons in the substantia nigra (Iravani et al., 2006; Gregoire et al., 2009; Marin et al., 2009); and (iii) in clinical trials, sarizotan, buspirone, and tandospirone alleviated dyskinesia in PD patients (Bonifati et al., 1994; Kannari et al., 2002). At a neurochemical level, 5-HT<sub>1A</sub> receptor agonists increase dopamine release in frontal cortex, as mentioned above, and modify the activity of cortico-striatal glutamatergic projections. Such influence, possibly involving inhibition of glutamate in the striatum may underlie the capacity of 5-HT<sub>1A</sub> receptor agonists to facilitate movement control (Dupre et al., 2011; Huot et al., 2011). Table 1 lists drugs currently under clinical testing that possess serotonin 5-HT<sub>1A</sub> receptor agonist activity.

Insofar as such observations may be relevant to Rett syndrome, they suggest that activation of 5-HT<sub>1A</sub> receptors may alleviate some of the disturbed motor function, including dyskinesia and dystonia, which constitute a source of poor movement control in RTT patients. Nevertheless, experimental investigation is necessary to substantiate this hypothesis, for example by examining the motor sensitivity of MeCP2 mice to dopamine receptor blockade (catalepsy induction) and whether 5-HT<sub>1A</sub> receptor agonists can protect against such responses. It should also be noted that the therapeutic potential of current 5-HT<sub>1A</sub> agonists suffers from some important limitations. Prominent among these is poor selectivity of the drugs with respect to cross-reacting targets. Indeed, buspirone also acts as a dopamine D2 receptor antagonist (Peroutka, 1985), and sarizotan is a weak D2 receptor partial agonist (Bartoszyk et al., 2004; Newman-Tancredi et al., 2005; Bruins Slot et al., 2006), and may act as a functional antagonist. This suggests again that high selectivity for 5-HT<sub>1A</sub> receptors is an important requirement to avoid concurrent off-target blockade of dopamine receptors. Secondly, drugs such as eltoprazine, buspirone, and tandospirone possess only modest agonist efficacy at 5-HT<sub>1A</sub> receptors. Thus, even at high doses, they are only able to partially activate the receptor (Newman-Tancredi et al., 2003), suggesting that optimal motor control by 5-HT<sub>1A</sub> Receptors may necessitate high-efficacy agonist stimulation. The novel 5-HT<sub>1A</sub> receptor agonist, NXL-101 (also known as F15599) constitutes a promising advance in view of its exceptional 5-HT<sub>1A</sub> receptor selectivity, high agonist efficacy and “biased agonist” profile (Newman-Tancredi et al., 2009), potently activating post-synaptic cortical 5-HT<sub>1A</sub> heteroreceptors (Llado-Pelfort et al., 2010). In vivo, NXL-101 exhibits pro-motor influence in rats with dopaminergic lesions, potent antidepressant-like properties (Assie et al., 2010), pro-cognitive activity (Depoortere et al., 2010); and, in MeCP2 mice, reverses respiratory disturbance (Levitt et al., 2013), properties that would be desirable in a pharmacotherapy strategy for Rett syndrome.

CONCLUSIONS

The severe autonomic phenotype of Rett syndrome has the greatest impact on patient’s health and quality of life, closely followed by motor deficits. 5-HT<sub>1A</sub> agonists have shown promising ability to alleviate brainstem, extrapyramidal and mood dysfunction in pre-clinical studies. In particular, a new class of selective “biased agonists” that target post-synaptic heteroreceptors shows less potential for competing or undesirable side effects. However, further rigorous pre-clinical testing in different mouse models of Rett syndrome is needed, especially in regards to motor dysfunction. In mouse models, the syndrome is reversible if MeCP2 function is rescued, but a cure applicable to humans is uncertain and may be many years away. In the meantime, there is need for drug therapies that are tolerated upon long term treatment and capable of alleviating the life-threatening autonomic symptoms.

AUTHOR CONTRIBUTIONS

Ana P. Abdala and Adrian Newman-Tancredi drafted the manuscript; Ana P. Abdala, John M. Bissonnette, and Adrian Newman-Tancredi revised it critically for important intellectual content; and approved the final version to be published; and are accountable for all aspects of the work.

ACKNOWLEDGMENTS

Ana P. Abdala is funded by the International Rett Syndrome Foundation and the National Institutes of Health (R01 NS069220). John M. Bissonnette is funded by the Rett Syndrome Research Trust, the NewLife Foundation and the International Rett Syndrome Foundation.

REFERENCES


www.frontiersin.org

May 2014 | Volume 5 | Article 205 | 5


Iravani, M. M., Tayarani-Binaiz, K., Chou, W. B., Jackson, M. J., and Jemnier, P. (2006). In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated pri-mates, the selective 5-hydroxytryptamine 1a agonist (R)+(-)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disabil-ity. *J. Pharmacol. Exp. Ther.* 319, 1225–1234. doi: 10.1124/jpet.106.110429


Frontiers in Physiology | Integrative Physiology

May 2014 | Volume 5 | Article 205 | 6
Abdala et al. Novel therapy for Rett syndrome


**Conflict of Interest Statement:** Adrian Newman-Tancredi has received consulting and/or speaker honoraria from pharmaceutical companies. He is Chief Scientific Officer and stockholder at Neurolixis.

Received: 11 April 2014; accepted: 12 May 2014; published online: 30 May 2014.


This article was submitted to Integrative Physiology, a section of the journal Frontiers in Physiology.

Copyright © 2014 Abdala, Bissonnette and Newman-Tancredi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.